Roche and Exiqon have agreed to jointly market Roche Applied Science's RealTime ready custom quantitative PCR assays with Exiqon's miRcury LNA Universal RT microRNA qPCR system, the companies said this week.
The co-marketing agreement builds on a licensing agreement related to the same technologies that has been in place since at least 2005, when Roche licensed Exiqon's locked nucleic acid technology to manufacture qPCR assays based on its universal probe library.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
